Human Milk Oligosaccharides (HMO) Market to Reach US$ 1,386.9 Million by 2033 at 20.1% CAGR; Key Players: Nestlé Health Science, Glycom, and Jennewein Biotechnologie

The global Human Milk Oligosaccharides (HMO) Market is projected to expand from USD 320.4 million in 2025 to USD 1,386.9 million by 2033, registering a CAGR of 20.1% during the forecast period 2026-2033. The market is driven by growing awareness of infant gut health, increasing demand for advanced infant nutrition products, and rising research into the benefits of human milk oligosaccharides. Advancements in biotechnology, microbial fermentation, and precision nutrition are supporting the commercial production of HMOs. Expanding applications in infant formula, dietary supplements, and functional nutrition are further contributing to market growth.

A major shift toward science-backed, gut-health-focused, and nutritionally advanced infant feeding solutions is creating new opportunities across infant formula manufacturers, food and beverage companies, biotechnology firms, and nutritional research organizations. Increasing incorporation of HMOs into infant nutrition products is supporting the development of formulations designed to promote beneficial gut microbiota and immune system development. The market is poised for significant expansion through 2033 as investments in HMO production technologies, growing consumer awareness, and continued innovation in infant nutrition accelerate the adoption of human milk oligosaccharide-based products.

Get a Free Sample PDF of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/human-milk-oligosaccharides-market?sai-v

Recent Developments
September 2026: The global HMO market is witnessing growing demand for multi-HMO formulations, infant nutrition innovation, and microbiome-focused ingredients.

September 2026: Manufacturers are expanding HMO applications beyond infant formula into functional nutrition, digestive health, and healthy-aging products.

August 2026: dsm-firmenich continued expanding its HMO portfolio across Asian markets, including regulatory approvals for 3′-sialyllactose in China, Malaysia, and Thailand.

July 2026: Infant nutrition manufacturers are increasing their focus on complex HMO blends, supporting product differentiation and improvements in formula composition.

June 2026: H&H Group launched its Biostime π-star infant formula in Mainland China, featuring six HMOs following the implementation of updated national standards.

May 2026: Regulatory developments across Asia-Pacific are supporting broader HMO adoption, product innovation, and potential cost efficiencies in infant nutrition.

Mergers & Acquisitions
Global: HMO manufacturers are focusing on strategic partnerships, technology licensing, and production capacity expansion to strengthen specialty ingredient portfolios.

Industry collaborations: Ingredient suppliers and infant formula companies are developing partnerships to support HMO integration, regulatory compliance, and product commercialization.

Strategic investments: Biotechnology companies are investing in precision fermentation, scalable production systems, and advanced purification technologies for HMO manufacturing.

Portfolio expansion: Market participants are exploring opportunities across infant nutrition, functional foods, dietary supplements, and microbiome-focused health products.

Key Players
Elicityl SA | Medolac Laboratories | Inbiose NV | Glycosyn | ZuChem | Jennewein Biotechnologie GmbH | Glycom A/S | Dextra Laboratories Limited | DuPont Nutrition & Health | Nestlé Health Science | Others

Key Highlights
Nestlé Health Science - Holds a 18% share, supported by its nutrition science expertise, infant nutrition portfolio, and global distribution network.

Glycom A/S - Holds a 15% share, driven by its human milk oligosaccharide (HMO) production capabilities and biotechnology expertise.

Jennewein Biotechnologie GmbH - Holds a 13% share, backed by its specialized HMO research, microbial fermentation, and ingredient development technologies.

Glycosyn - Holds a 12% share, supported by its HMO innovation, proprietary production technologies, and infant nutrition applications.

DuPont Nutrition & Health - Holds a 10% share, strengthened by its food biotechnology expertise and functional nutrition ingredient solutions.

Inbiose NV - Holds a 9% share, driven by its expertise in glycan synthesis and advanced HMO manufacturing technologies.

Medolac Laboratories - Holds a 8% share, supported by its human milk-based nutritional solutions and infant nutrition research.

Elicityl SA - Holds a 6% share, backed by its glycan research, oligosaccharide development, and biotechnology capabilities.

ZuChem - Holds a 5% share, supported by its microbial biotechnology and carbohydrate engineering expertise.

Dextra Laboratories Limited - Holds a 2% share, driven by its specialty carbohydrate and oligosaccharide development capabilities.

Others - Hold a combined 2% share, representing emerging biotechnology companies and specialized HMO ingredient manufacturers.

Buy now to access the full report: https://www.datamintelligence.com/buy-now-page?report=human-milk-oligosaccharides-market?sai-v

White Space Opportunities
Infant Nutrition Innovation: Growing demand for advanced infant nutrition products creates opportunities for HMO-enriched formula development.

New HMO Structures: Research into additional human milk oligosaccharide structures can expand functional applications in infant nutrition.

Prebiotic Applications: HMO ingredients offer opportunities for supporting gut microbiome development and digestive health.

Immune Health Formulations: Increasing interest in immune-supporting nutrition creates opportunities for HMO-based functional products.

Adult Nutrition: Research into HMO applications for adult gut and immune health may support future market diversification.

Emerging Market Expansion: Improving awareness of premium infant nutrition and rising disposable incomes create opportunities across developing economies.

Industry Developments
HMO Production Expansion: Manufacturers are scaling microbial fermentation and biotechnology-based production to increase HMO availability.

Formula Fortification: Infant formula producers are incorporating HMOs into formulations to more closely replicate selected functional components of human milk.

Product Portfolio Expansion: Companies are developing combinations of multiple HMOs, including 2'-FL, 3-FL, and LNnT.

Research Collaborations: Biotechnology companies, nutrition manufacturers, and research institutions are advancing studies on HMO functionality.

Regulatory Approvals: Regulatory developments across major markets are influencing the commercialization and use of HMO ingredients.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/human-milk-oligosaccharides-market?sai-v

Key Segments
➥ By Product

Lacto-N-neotetraose (LNnT): A structurally complex HMO used in infant nutrition and research due to its potential role in supporting gut microbiota and immune function.

Lacto-N-tetraose (LNT): A naturally occurring HMO that supports research and product development focused on infant gut health and nutritional benefits.

2'-Fucosyllactose (2'FL): One of the most widely studied HMOs, used in infant formula and nutritional products to support the development of a healthy gut microbiome.

3'-Fucosyllactose (3'FL): A fucosylated HMO being explored for its potential prebiotic and immune-supporting properties in infant nutrition and functional formulations.

3'-Sialyllactose (3'SL): A sialylated HMO studied for its potential role in neurological development, immune function, and intestinal health.

6'-Sialyllactose (6'SL): A sialylated oligosaccharide researched for its potential contribution to brain development, immune modulation, and gut health.

Others: Include additional HMOs developed through biological, enzymatic, or synthetic production methods for nutritional and functional applications.

➥ By Type

Neutral: Includes HMOs without an acidic charge, such as fucosylated and non-fucosylated neutral oligosaccharides used in infant nutrition and functional formulations.

Acidic: Covers sialylated HMOs containing acidic groups, which are studied for their potential roles in immune function, gut health, and neurological development.

Others: Include additional structural categories of HMOs developed for specialized nutritional and research applications.

➥ By Application

Infant Formula: HMOs are incorporated into infant formula to help replicate selected functional components of human breast milk and support gut microbiome development.

Dietary Supplements: Used in nutritional supplements designed to support digestive health, immune function, and microbiome balance.

Functional Food and Beverages: HMOs are incorporated into food and beverage formulations to provide targeted nutritional and prebiotic benefits.

Others: Include applications in pharmaceuticals, clinical nutrition, animal nutrition, and specialized research products.

Explore the report here: https://www.datamintelligence.com/research-report/human-milk-oligosaccharides-market

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.